{"id":"W4310295951","doi":"10.1177/13524585221137502","title":"Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry","year":2022,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"EMD Serono; Multiple Sclerosis Society; Università di Catania; Multiple Sclerosis Society of Canada; H. Lundbeck A/S; International Progressive MS Alliance; Universität Basel; Merck KGaA; Univerzita Karlova v Praze; Biogen; Celgene; Alexion Pharmaceuticals; Teva Pharmaceutical Industries; GlaxoSmithKline; Sanofi; Fondation Brain Canada; Pfizer","keywords":"Teriflunomide; Cladribine; Fingolimod; Medicine; Discontinuation; Multiple sclerosis; Dimethyl fumarate; Internal medicine; Hazard ratio; Clinical trial; Confidence interval; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01115933,0.0003627762,0.001520788,0.0009029684,0.0002288693,0.001136374,0.0008695016,0.0004859318,0.002046916],"category_scores_gemma":[0.01934845,0.0002445714,0.002297959,0.001854126,0.0002726288,0.0008606705,0.0007494318,0.0005759526,0.0003684179],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007220571,"about_ca_system_score_gemma":0.0007186942,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00209983,"about_ca_topic_score_gemma":0.002573219,"domain_scores_codex":[0.990213,0.005003577,0.001372853,0.001339552,0.001842994,0.0002280401],"domain_scores_gemma":[0.9747791,0.008607925,0.01214204,0.001990092,0.001695784,0.0007850715],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1472783,0.0007802347,0.7731692,0.002816425,0.0194058,0.00009690389,0.0002691303,0.001670814,0.001185975,0.000293812,0.005071427,0.04796199],"study_design_scores_gemma":[0.01377729,0.009358983,0.9599612,0.0004768429,0.009160082,0.0003954292,0.0001633637,0.001459168,0.00105619,0.0001313685,0.004009759,0.00005036332],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.962537,0.007753926,0.0004250793,0.0001858668,0.00003483698,0.0002855078,0.02636643,0.00003640596,0.002374844],"genre_scores_gemma":[0.9739136,0.002204053,0.0004649406,0.0001513339,0.00005193828,0.0002545141,0.02267282,0.00002609729,0.0002607906],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01115933,"threshold_uncertainty_score":0.05901688,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2799543506146697,"score_gpt":0.3646852724158959,"score_spread":0.08473092180122616,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}